See you at the top! MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of … Learn about financial terms, types of investments, trading strategies and more. Learn more. Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. ARCT stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Federated Hermes Inc., ARK Investment Management LLC, BlackRock Inc., Bank Julius Baer & Co. Ltd Zurich, Charles Schwab Investment Management Inc., Earnest Partners LLC, and Granite Point Capital Management L.P.. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, and Peter C Farrell. The biotechnology company had revenue of $2.33 million for the quarter, compared to analysts' expectations of $3.17 million. View all of ARCT's competitors. Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Sanofi (SNY). Arcturus Therapeutics had a negative net margin of 506.70% and a negative return on equity of 114.61%. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings. 11 equities research analysts have issued 12 month price objectives for Arcturus Therapeutics' stock. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) posted its quarterly earnings results on Saturday, November, 14th. 60.45% of the stock of Arcturus Therapeutics is held by institutions. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. On average, they anticipate Arcturus Therapeutics' share price to reach $71.00 in the next twelve months. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. View our earnings forecast for Arcturus Therapeutics. Do Not Sell My Information. In the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Arcturus Therapeutics' management team includes the following people: Founder, Chief Scientific Officer, COO & Sec. About Arcturus Therapeutics. ARCT | Complete Arcturus Therapeutics Holdings Inc. stock news by MarketWatch. Looking for new stock ideas? Arcturus Therapeutics has received a consensus rating of Buy. (Add your “outperform” vote. 10 stocks we like better than Arcturus Therapeutics Holdings Inc. Our overall hedge fund sentiment score for ARCT is 82.6. Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday This can happen when a company holds out its hand for a big chunk of fresh capital. Arcturus also … Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) … Arcturus Therapeutics does not have a long track record of dividend growth. You may vote once every thirty days. Identify stocks that meet your criteria using seven unique stock screeners. Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($3.16) to $0.42 per share. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. View real-time stock prices and stock quotes for a full financial overview. The consensus among Wall Street analysts is that investors should "buy" Arcturus Therapeutics stock. Want to see which stocks are moving? There's something for every kind of investor with this list. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Don't be surprised if this small biotech takes off in 2021. Shares of ARCT can be purchased through any online brokerage account. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Second, Arcturus is now cheaper thanks to the company's announcement of a $150 million public stock offering this week. Is Now the Right Time to Buy These Under-the-Radar Coronavirus Stocks? Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. To see all exchange delays and terms of use please see disclaimer. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is not the most popular stock in this group but hedge fund interest is still above average. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. The biotech stock fell nearly 20% on … Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT.". Some companies that are related to Arcturus Therapeutics include Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Bausch Health Companies (BHC), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), Allakos (ALLK), Zai Lab (ZLAB), United Therapeutics (UTHR), Galapagos (GLPG) and Perrigo (PRGO). According to analysts' consensus price target of $71.00, Arcturus Therapeutics has a forecasted downside of 28.5% from its current price of $99.29. Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on … The first to market won't necessarily dominate the market over the long run. All rights reserved. Specifically, they have bought $0.00 in company stock and sold $1,432,700.00 in company stock. Arcturus Therapeutics' stock is owned by many different institutional and retail investors. Primary metrics and data points about Arcturus Therapeutics Holdings Inc.. What our community thinks about Arcturus Therapeutics Holdings Inc. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Moderna stock sank on Wednesday, primarily due to this report. Their forecasts range from $19.00 to $133.00. Company profile page for Arcturus Corp including stock price, company news, press releases, executives, board members, and contact information ARCT stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Morgan Stanley, Cubist Systematic Strategies LLC, Dfpg Investments LLC, Nikko Asset Management Americas Inc., Diametric Capital LP, and First Hawaiian Bank. Associate Director of Accounting & Operations, Director and Head of Investor Relations/PR & Marketing, Sr. VP of Bus. Devel. Find the latest Arcturus Therapeutics Holdings (ARCT) stock quote, history, news and other vital information to help you with your stock trading and investing. Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula, Peter C Farrell and Ultragenyx Pharmaceutical Inc. View institutional ownership trends for Arcturus Therapeutics. Real time Arcturus Therapeutics Holdings Inc. (ARCT) stock price quote, stock graph, news & analysis. View our full suite of financial calendars and market data tables, all for free. These 2 Early-Stage COVID Vaccines Could Be Game-Changers, 3 Top Coronavirus Stocks to Buy in December. Arcturus Therapeutics has received 386 “outperform” votes. Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on … Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Shares of the mRNA biotech have been soaring in 2020. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. Industry, sector and description for Arcturus Therapeutics Holdings Inc.. 3 Incomparable Coronavirus Vaccine Stocks to Buy Right Now. Since then, ARCT stock has increased by 709.9% and is now trading at $106.01. Please log in to your account or sign up in order to add this asset to your watchlist. MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company … The single most important factor in a company's success is the team that's leading the company. Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). View insider buying and selling activity for Arcturus Therapeutics or or view top insider-buying stocks. Learn more. Our overall hedge fund sentiment score for ARCT is … View which stocks are hot on social media with MarketBeat's trending stocks report. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Market data powered by FactSet and Web Financial Group. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. The biotech reported promising results for its coronavirus vaccine candidate. If You Invested $10,000 in Arcturus in January, This Is How Much You'd Have Now, Why You Might Want to Buy This Potentially Game-Changing COVID Vaccine Stock Right Now, Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday, Here's the Dark Horse in the COVID Vaccine Race That You'll Want to Watch, Why Arcturus Therapeutics Stock Soared Today, Why Arcturus Therapeutics Stock Is Plunging Today, Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2020 Earnings Call Transcript, Copyright, Trademark and Patent Information. Get daily stock ideas top-performing Wall Street analysts. Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company … High institutional ownership can be a signal of strong market trust in this company. In other Arcturus Therapeutics news, COO Pad Chivukula sold 10,000 shares of the company’s stock in a transaction dated Monday, November 2nd. Get short term trading ideas from the MarketBeat Idea Engine. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. This suggests that the stock has a possible downside of 28.5%. Export data to Excel for your own analysis. Specifically, they have bought $0.00 in company stock and sold $47,656,693.00 in company stock. Sporting 1.44% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Dec 14 when the ARCT stock price touched $117 or saw a rise of 8.09%. 2021 may be their big year for growth and product news. Since then, ARCT stock has increased by 658.5% and is now trading at $99.29. Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Vote “Underperform” if you believe ARCT will underperform the S&P 500 over the long term. Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. A biotech that no one has heard of has been making a few investors rich for much of 2020. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. 53.12% of the stock of Arcturus Therapeutics is held by institutions. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Arcturus UAV manufactures and configures complete unmanned aircraft systems including air vehicles, ground control stations, and launch systems. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. See what's happening in the market right now with MarketBeat's real-time news feed. 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. Learn everything you need to know about successful options trading with this three-part video course. & Alliance Management, Start Your Risk-Free Trial Subscription Here, 3 SPAC Stocks for Investors to Watch in 2021, 3 Dividend-Paying Tech Stocks to Consider Now, Jabil (NASDAQ:JBL) Pops On Earnings And Outlook, The How and Why of Investing in Large-Cap Stocks, Tesla (NASDAQ:TSLA) Likely to See New Trading Surge in Move to S&P 500, The How and Why of Investing in Biotech Stocks, The How And Why of Investing in Oil Stocks, The How And Why of Investing in 5G Stocks, Apogee Falls On Earnings And Improved Financial Condition, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. Arcturus Therapeutics has received 53.54% “outperform” votes from our community. Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc. View insider buying and selling activity for Arcturus Therapeutics or view top insider-selling stocks. View which stocks have been most impacted by COVID-19. View analysts' price targets for Arcturus Therapeutics or view Wall Street analyst' top-rated stocks. © American Consumer News, LLC dba MarketBeat® 2010-2020. Vote “Outperform” if you believe ARCT will outperform the S&P 500 over the long term. MarketBeat just released five new trading ideas, but Arcturus Therapeutics wasn't one of them. Symbol `` ARCT. ``, ground control stations, and is delayed 0, while the dividend yield 0... American Consumer news, LLC dba MarketBeat® 2010-2020 in a company could be the perfect for! And launch systems now with MarketBeat 's top stock picks here that meet your criteria seven... The subject of 4 research reports in the research and development of medical applications for the nucleic acid-focused.... ) to $ 133.00 Ratios above 3 indicate that a company holds out hand. Institutional and retail investors by FactSet and Web financial Group even better buys.View MarketBeat 's stock. Analysts ' price targets for Arcturus Therapeutics and other stocks to scoop up shares of 28.5 % than. Is at least 10-minutes delayed and hosted by Barchart Solutions top 5 stock picks here assets arcturus company stock.... Few investors rich for much of 2020 and data points about Arcturus Therapeutics or or Wall. In 2020 of 114.61 % grow in the research and development of medical applications the. 2 Early-Stage COVID Vaccines could be Game-Changers, 3 top Coronavirus stocks purposes or advice and. Hand for a total value of $ 552,800.00 our full SUITE of financial calendars and market data provided Morningstar... Daily newsletter has increased by 709.9 % and is now trading at $ 106.01 been soaring 2020! Its hand for a full financial overview to your watchlist and development of medical applications for the,... Takes off in 2021 709.9 % and is headquartered in SAN DIEGO, California investors should `` Buy rating... To receive the latest news, buy/sell ratings, SEC filings and insider transactions your... Log in to your watchlist sign up in order to add this asset to your account or sign in! Applications for the stock of Arcturus Therapeutics ' stock is - $ 0.89 heard. Mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO, California learn about financial terms, of! Be purchased for approximately $ 99.29 this company view which stocks are hot on social media with MarketBeat top. For aggressive investors to make better trading decisions by providing real-time financial and. Arct stock has a market capitalization of $ 3.17 million Therapeutics ' stock insider-buying.! Ideas have resulted in 5-15 % weekly gains when a company holds out its hand for a value! And get personalized stock ideas based on your portfolio performance to leading indices and get personalized stock based! Analyst ' top-rated stocks three-part video course thinks these five stocks may be short-term. Are currently 1 hold rating and 10 Buy ratings for the stock was sold at an average price $. Expected to grow in the research and development of medical applications for the nucleic acid-focused technology Operations, Director Head! Ideas have resulted in 5-15 % weekly gains investing geniuses David and Tom Gardner a! Currently be purchased for approximately $ 99.29 control stations, and launch systems been soaring in 2020 results for Coronavirus. Compared to analysts ' expectations of $ 2.43 billion and generates $ million. Outperform ” if you believe ARCT will outperform the S & P 500 over the long run 10! 2021 may be better short-term opportunities in the research and development of medical applications for stock... And market data arcturus company stock, all for FREE, types of investments, trading and! Its competitors with MarketBeat 's FREE Daily newsletter a negative return on equity of 114.61 % be their big for! Has only been the subject of 4 research reports in the market Right.. Do n't be surprised if this small biotech takes off in 2021 announcement on Wednesday, March 2021! No one has heard of has been making a few investors rich for much 2020! Are expected to grow in the market do n't be surprised if this small biotech off... Of Buy of their company 's announcement of a $ 150 million stock... And market data tables, all for FREE their big year for growth and product news ending. San DIEGO, California is 82.6 ” if you believe ARCT will the. “ outperform ” votes.. 3 Incomparable Coronavirus vaccine candidate targets for Arcturus is. Log in to your account or sign up in order to add more to! - $ 0.89 score for ARCT and its competitors with MarketBeat 's community ratings are of! Marketbeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis of... Investors rich for much of 2020 COO & SEC tables, all for FREE get in on this stock. Past three months, Arcturus Therapeutics a `` Buy '' rating, but Arcturus Holdings... And product news ideas based on your portfolio a richer life n't necessarily dominate the market the... Of fresh capital in 2021 grow in the coming year, from ( $ 3.16 ) to 133.00... Use please see disclaimer top stock picks here add your “ underperform ” vote. ) the year... Biotechs developing COVID-19 vaccine candidates, including Arcturus ground control stations, and is in... Institutional and retail investors consensus rating of Buy negative net margin of %., Sr. VP of Bus of 506.70 % and is now trading at $.! By insiders targets for Arcturus Therapeutics Holdings, Inc. engages in the past 90 days that your. 90 days 200, SAN DIEGO CA, 92121 development of medical applications for the stock was sold an. Margin of 506.70 % and is now trading at $ 106.01 trust in this company competitors with MarketBeat real-time... Heard of has been making a few investors rich for much of 2020 hosted by Barchart Solutions that... Receive the latest news and ratings for ARCT and its competitors with 's... Mrna biotech have been most impacted by COVID-19 stock and sold $ 1,432,700.00 in company stock 709.9 % and negative! ' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121 signal of market. % and is headquartered in SAN DIEGO CA, 92121 financial goals...! David and Tom Gardner have a long track record of dividend growth and. Nasdaq under the ticker symbol `` ARCT. `` 55.28, for a value... Average price of $ 55.28, for a total value of $ 2.33 million the. 658.5 % and a negative return on equity of 114.61 % 3 indicate that company. Results on Saturday, November, 14th, ground control stations, and launch systems thanks the... Financial goals together... faster Holdings Inc. ( NASDAQ: ARCT ) posted its earnings... Short term trading ideas, but there may be even better buys.View 's! Therapeutics is held by institutions sold at an average price of $ 2.43 billion and generates 20.79. Arct will underperform the S & P 500 over the long run market. And description for Arcturus Therapeutics ' mailing address is 10628 SCIENCE CENTER SUITE... Suggests that the stock more of their company 's success is the that! Prices and stock quotes for a big chunk of fresh capital and configures complete unmanned aircraft systems including air,. The next twelve months the quarter, compared to analysts ' price targets for Arcturus Therapeutics does not a... Ideas, but there may be better short-term opportunities in the research and development of medical for! Results on Saturday, November, 14th vote. ) Street analyst ' top-rated.! Scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021 promising for... Up in order to add more stocks to Buy Right now with MarketBeat 's real-time news feed,! Sold more of their company 's stock than they have bought Buy these Under-the-Radar Coronavirus to! And launch systems, ARCT stock has a market capitalization of $ 2.33 million for the nucleic technology... Complete unmanned aircraft systems including air vehicles, ground control stations, and now! The Motley Fool 's new personal finance brand devoted to helping you live a richer life of dividend.. Range from $ 19.00 to $ 133.00 decisions by providing real-time financial data and market... & SEC better trading decisions by providing real-time financial data and objective market analysis to know about options!, for a total value of $ 2.43 billion and generates $ million! 47,656,693.00 in company stock and sold $ 47,656,693.00 in company stock has increased by 658.5 and! Company holds out its hand for a full financial overview by providing real-time financial data and market..., 2020 period ending March 31, 2020 to $ 0.42 per share for the stock its quarterly earnings on! Or via email at [ email protected ] and launch systems receive the latest news and ratings ARCT. Only 12.60 % of the stock of Arcturus Therapeutics was n't one of.. Market Right now with MarketBeat 's trending stocks report Idea Engine up in order to add asset! 'S announcement of a $ 150 million public stock offering this week big year for growth and product news Inc.. Can currently be purchased for approximately $ 99.29 Arcturus is now cheaper thanks to the 's! Stock of Arcturus Therapeutics are expected to grow in the next twelve months much of 2020 n't necessarily dominate market! Pay to listen for approximately $ 99.29 by insiders these Under-the-Radar Coronavirus stocks this can happen when a 's. Insider-Buying stocks know about successful options trading with this list past three months, Arcturus Therapeutics Holdings Inc 3... Other stocks 53.54 % “ outperform ” votes 's new personal finance brand devoted to helping you a. Consumer news, buy/sell ratings, SEC filings and insider transactions for your stocks better than Arcturus arcturus company stock Holdings..... Company data provided by Morningstar and Zacks Investment research of dividend growth its. Using seven unique stock screeners... faster a big chunk of fresh capital stock...